Diabetes and cardiovascular events in hypertensive patients.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  HYPERTENSION

• Publication date

  1999-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.HYP.33.5.1130PMID 10334799
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diabetes and arterial hypertension

  2004cited by this paper
• MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION

  2000influential reference
• Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment

  1998cited by this paper
• Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

  1998cited by this paper
• The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it?

  1997cited by this paper
• Antihypertensive Drug Therapy. The effect of JNC criteria on prescribing patterns and patient status through the first year.

  1996cited by this paper
• The Hypertension Optimal Treatment (HOT) Study in the United States.

  1996cited by this paper
• Undiagnosed Glucose Intolerance in the Community: the Isle of Ely Diabetes Project

  1995cited by this paper
• Antihypertensive Drug Therapy and the Initiation of Treatment for Diabetes Mellitus

  1993cited by this paper
• The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)

  1993cited by this paper
• Regional variation in ischemic heart disease incidence.

  1992cited by this paper
• Which antihypertensive drugs first--and why!

  1992cited by this paper
• Treatment-induced blood pressure reduction and the risk of myocardial infarction.

  1989influential reference
• The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

  1988cited by this paper
• Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up program, stratified by other risk factors. The Hypertension Detection and Follow-up Program Cooperative Research Group.

  1985cited by this paper
• Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study.

  1983cited by this paper
• Coincident hypertension. Deleterious effects on patients with hyperglycemia.

  1983cited by this paper
• The Bedford Survey: Ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics

  1982cited by this paper
• Impairment of glucose tolerance produced by diuretics and other drugs.

  1981cited by this paper
• Diabetes and Cardiovascular Risk Factors: The Framingham Study

  1979cited by this paper
• Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment.

  1976cited by this paper
• Hypertension control at the work site.

  1976influential reference
• Detection and treatment of hypertension at the work site.

  1975cited by this paper
• The identification of risk factors in employed populations.

  1974cited by this paper
• Role of blood pressure in cardiovascular morbidity and mortality.

  1974cited by this paper
• Factors associated with long-term survival of diabetics.

  1970cited by this paper
• Some aspects of hypertension in diabetes mellitus.

  1967cited by this paper
• Surgical teaching in the development of clinical competence.

  1967cited by this paper
• Regression Models and Life-Tables

  year unknowninfluential reference

• Incidence of Cardiovascular Events in Hypertensive Patients Based on the Quantity of Major Risk Factors According to the Isfahan Cohort Study

  2025cites this paper
• Deep Learning for Cardiovascular Risk Assessment: Proxy Features from Carotid Sonography as Predictors of Arterial Damage

  2025cites this paper
• Differences in the impact of newly diagnosed type 2 diabetes on cardiovascular mortality between normotensive and hypertensive individuals

  2024cites this paper
• Association of Fibroblast Growth Factor 23 with Blood Pressure in Primary Proteinuric Glomerulopathies

  2023cites this paper
• Cardiovascular Disease Risk Factors in Hypertensive Patients: A Case Study of Jimma University Medical Center

  2022cites this paper
• Interactive effects of serum ferritin and high sensitivity C-reactive protein on diabetes in hypertensive patients.

  2021cites this paper
• Efficiency (advantages) of ramipril in arterial hypertension and diabetes mellitus from the point of view of evidence-based medicine

  2020cites this paper
• Антиоксидантная терапия последствий ишемических инсультов, с позиции доказательной медицины

  2020cites this paper
• Non-enzymatic D-glucose plasmonic optical fiber grating biosensor.

  2019cites this paper
• Statins use and risk of new-onset diabetes in hypertensive patients: a population-based retrospective cohort study in Yinzhou district, Ningbo city, People’s Republic of China

  2018cites this paper
• Contribution and interaction of the low‐density lipoprotein cholesterol to high‐density lipoprotein cholesterol ratio and triglyceride to diabetes in hypertensive patients: A cross‐sectional study

  2018cites this paper
• Serum levels of undercarboxylated osteocalcin are related to cardiovascular risk factors in patients with type 2 diabetes mellitus and healthy subjects

  2017cites this paper
• Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese

  2017cites this paper
• In Vitro Drug Interactions Study of Lisinopril with Metformin

  2017cites this paper
• Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes.

  2016cites this paper
• Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial

  2016cites this paper
• Cardiovascular Risk Factors: Hypertension

  2016cites this paper
• Hypertension and Dyslipidemia in Patients with Pre-Diabetes: Dietary and Other Therapies

  2015cites this paper
• Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography.

  2015cites this paper
• 4B.04: COST-UTILITY OF ANGIOTENSIN-CONVERTING ENZYME INHIBITOR COMPARED TO THIAZIDE DIURETIC -BASED TREATMENT FOR HYPERTENSION IN ELDERLY AUSTRALIANS CONSIDERING DIABETES AS COMORBIDITY

  2015cites this paper
• Cost–Utility of Angiotensin-Converting Enzyme Inhibitor-Based Treatment Compared With Thiazide Diuretic-Based Treatment for Hypertension in Elderly Australians Considering Diabetes as Comorbidity

  2015cites this paper
• Antidiabetic effect of green rooibos (Aspalathus linearis) extract in cultured cells and type 2 diabetic model KK-Ay mice

  2015cites this paper
• The role of beta-blockers in the treatment of arterial hypertension: what do we know today

  2015cites this paper
• General Characteristics, Self-Efficacy, and Diet Control of Hypertension Patients at a Diabetes Admission Control Center in the Jeollanma-do Area

  2015cites this paper
• G-protein-coupled receptor kinase 2 and endothelial dysfunction: molecular insights and pathophysiological mechanisms

  2015cites this paper
• Racial/Ethnic differences in medication uptake and clinical outcomes among hospitalized cardiovascular patients with hypertension and diabetes.

  2015cites this paper
• Recent developments in blood glucose sensors

  2015cites this paper
• Comparison of the Long-Term Efficacy and Some Metabolic Effects of Initiating Therapy with Amlodipine or Hydrochlorothiazide in Hypertensive Type 2 Diabetic Nigerians.

  2014cites this paper
• Alteration in fasting glucose after prolonged treatment with a thiazide diuretic.

  2014cites this paper
• Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study.

  2014cites this paper
• Antihypertensive combination therapy in primary care offices: results of a cross-sectional survey in Switzerland

  2014cites this paper
• Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes

  2013cites this paper
• How should we treat hypertension and dyslipidemia in patients with prediabetes?

  2013cites this paper
• Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension.

  2013cites this paper
• The concomitance of hypertension and diabetes exacerbating retinopathy: the role of inflammation and oxidative stress.

  2013cites this paper
• Risk prediction in stable angina pectoris

  2013cites this paper
• Urgent Announcement From the Editor-in-Chief Concerning Article Retractions

  2013cites this paper
• The Effects of 6 Months Lifestyle Coaching Program for Adults with Hypertension

  2013cites this paper
• Phytochemistry and mode of action of some tropical spices in the management of type-2 diabetes and hypertension

  2013cites this paper
• The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence

  2012cites this paper
• Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression

  2012cites this paper
• [Arterial Hypertension - when are which combination therapies useful?].

  2012cites this paper
• Genetic, pharmacogenetic, and pharmacotherapeutic risk factors for thiazide-induced dysglycemia

  2012cites this paper
• Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.

  2012cites this paper
• Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment

  2012cites this paper
• Cacao liquor procyanidin extract improves glucose tolerance by enhancing GLUT4 translocation and glucose uptake in skeletal muscle

  2012influential citation
• Retraction：Effects of Valsartan on Cardiovascular Morbidity and Mortality in High-Risk Hypertensive Patients With New-Onset Diabetes Mellitus

  2012cites this paper
• Inhibitor of G protein-coupled receptor kinase 2 normalizes vascular endothelial function in type 2 diabetic mice by improving β-arrestin 2 translocation and ameliorating Akt/eNOS signal dysfunction.

  2012influential citation
• Clinical Perspective on the Management of Hypertension

  2011cites this paper
• Why Are We Still Using Hydrochlorothiazide?

  2011cites this paper
• Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex)

  2011cites this paper
• Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic β-cells

  2011cites this paper
• Cardiovascular Outcomes in Framingham Participants With Diabetes: The Importance of Blood Pressure

  2011cites this paper
• Evaluation of Nutrition Education for Hypertension Patients Aged 50 Years and Over

  2011cites this paper
• New-onset diabetes and cardiovascular events in essential hypertensives: a 6-year follow-up study.

  2011cites this paper
• [Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial].

  2011cites this paper
• Marcadores bioquímicos de lesión endotelial, sistema fibrinolítico y microalbuminuria en HTA esencial

  2011cites this paper
• Effect of antihypertensive drug-associated diabetes on cardiovascular risk.

  2010cites this paper
• Is Pulse Pressure a Predictor of New-Onset Diabetes in High-Risk Hypertensive Patients?

  2010influential citation
• Current place of beta-blockers in the treatment of hypertension.

  2010cites this paper
• Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.

  2010cites this paper
• The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis.

  2010cites this paper
• Treatments for Hypertension Thiazide-Type Diuretics and -Adrenergic Blockers as First-Line Drug

  2010cites this paper
• Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice

  2010cites this paper
• Europejskie zalecenia dotyczące leczenia nadciśnienia tętniczego: stanowisko Europejskiego Towarzystwa Nadciśnienia Tętniczego 2009

  2010cites this paper
• Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation.

  2010cites this paper
• Metabolic Syndrome in Hypertension - Treatment Challenges and Goals Hypertension

  2009cites this paper
• Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.

  2009cites this paper
• Glucose and Non‐glucose Predictors of Future Onset of Type 2 Diabetes in Newly Diagnosed Essential Hypertensives

  2009cites this paper
• Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects

  2009cites this paper
• Heart rate variability in patients with stable angina pectoris

  2009cites this paper
• Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes

  2009cites this paper
• Chapter 13 Hypertension

  2009cites this paper
• Antihypertensive therapy, new-onset diabetes, and cardiovascular disease

  2009cites this paper
• Cardioprotection with beta‐blockers: myths, facts and Pascal’s wager

  2009cites this paper
• Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

  2009cites this paper
• [Effects of antihypertensive drugs on glucose metabolism and cardiovascular events].

  2009cites this paper
• The ADVANCE Trial

  2009cites this paper
• High-risk patients with hypertension: Are we doing enough?

  2008cites this paper
• The Clinical Significance of New-Onset Diabetes Mellitus in Hypertension

  2008cites this paper
• CB1 Antagonism in the Management of Abdominal Obesity

  2008cites this paper
• The Clinical Significance of Metabolic Syndrome in Hypertension: Metabolic Syndrome Increases Cardiovascular Risk

  2008cites this paper
• Risk/Benefit Assessment of &bgr;-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension

  2008cites this paper
• Risk of hypoglycemia associated with thyroid agents is increased in patients with liver impairment.

  2008cites this paper
• Morbidity and mortality trials

  2008cites this paper
• Should-blockers and diuretics remain as first line therapy for hypertension ? Thiazide-Type Diuretics and-Adrenergic Blockers as First-Line Drug Treatments for Hypertension

  2008cites this paper
• Should -blockers and diuretics remain as first line therapy for hypertension?

  2008cites this paper
• Is New-Onset Diabetes Mellitus Important?

  2008cites this paper
• β-Blockers and Diuretics in the Treatment of Hypertension

  2008cites this paper
• Hypertension, concurrent cardiovascular risk factors and mortality: the Singapore Cardiovascular Cohort Study

  2008cites this paper
• The management of the type 2 diabetic patient with hypertension – too late and too little: Suggested improvements

  2008cites this paper
• THE RISK OF DEVELOPING DIABETES IN HYPERTENSION : -Insulin sensitivity, AT-1 receptor blockade and sympathetic activity

  2008cites this paper
• Additional Small Amounts of Diuretics Improve Blood Pressure Control at Low Cost without Disadvantages in Blood Sugar Metabolism

  2008cites this paper
• New onset diabetes during antihypertensive therapy.

  2008cites this paper
• CB1 Blockade and Hypertension

  2008cites this paper
• 2007 ESH‐ESC Guidelines for the management of arterial hypertension

  2007cites this paper
• La diabetes mellitus entendida como una enfermedad cardiovascular de origen metabólico

  2007cites this paper
• [Global treatment of cardiovascular risk in the hypertensive patient].

  2007cites this paper
• 2007 Guidelines for the management of arterial hypertension

  2007cites this paper
• A Critical Review of the Evidence

  2007cites this paper